A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma

NCT01046266 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: RO5083945
DRUG: cetuximab

Sponsor

Hoffmann-La Roche